BUZZ-Durect up on FDA's 'breakthrough therapy' tag for liver disease treatment

Reuters05-21

** Shares of drugmaker Durect Corp rise 3.8% to $1.1

** U.S. FDA has granted "breakthrough therapy" designation (BTD) to DRRX's treatment for patients with severe alcohol-associated hepatitis (AH)

** AH is an acute form of liver disease associated with long-term heavy alcohol intake, often following a recent period of increased consumption

** Company plans to confirm the efficacy and safety of the treatment candidate, larsucosterol, in a registrational late-stage trial

** BTD is meant to speed up the development and review of drugs to treat a serious condition or unmet medical need

** Including session's gain, stock up more than 80% YTD

(Reporting by Pratik Jain in Bengaluru)

((Pratik.Jain@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment